DYCONEX acquired by Somacis
Context
The acquisition of DYCONEX by SOMACIS executes a strategic consolidation within the highly regulated medical printed circuit board market, officially transferring ownership from the target's former parent entity, Micro Systems Technologies. Completed on July 31, 2024, this cross-border transaction integrates a specialized Swiss manufacturing asset into the acquiring group's broader European industrial portfolio. The structural mechanics of this buyout occur concurrently with a major capitalization shift at the acquiring level; on July 25, 2024, the private equity firm Bain Capital formally acquired a controlling stake in the buyer from Chequers Capital. Under the finalized financial architecture, Chequers Capital actively retains a minority shareholding position in the newly formed consolidated entity alongside the primary sponsor. This secondary buyout structure provides institutional capital to immediately execute the bolt-on integration of the target, acting as the first major external growth initiative under the new private equity mandate. Strategically, this external growth maneuver is explicitly designed to instantly bridge a critical gap in the buyer's medtech exposure. By absorbing the target's proprietary intellectual property surrounding flexible and rigid-flex circuit solutions, the new parent company significantly upgrades its internal technological capabilities without incurring the lengthy timeline of organic research and development. The integration thesis relies on cross-selling these specialized medical components through the buyer's established global distribution channels, fundamentally expanding its market reach beyond its historical aerospace and defense strongholds. The institutional backing from the new controlling fund is structured to finance immediate commercial synergies while optimizing the combined supply chain architecture across multiple jurisdictions. Throughout the competitive transaction process, the sell-side execution was managed exclusively by the investment banking firm Houlihan Lokey, which provided comprehensive financial advisory and transaction support to the selling parent group and its subsidiary. This advisory mandate navigated the complex carve-out dynamics required to separate the entity from Micro Systems Technologies and seamlessly align it with the buyer's newly restructured capital table. By finalizing this agreement, the financial sponsors orchestrate a definitive scale-up in the high-end industrial technology sector, establishing a comprehensively integrated platform capable of aggressively competing for premium international manufacturing contracts.
DYCONEX, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the TMT (Tech, Media, Telecom) sector (15.1x).
-> Deep-dive in TMT (Tech, Media, Telecom) market trends
Target
Located in Bassersdorf, Switzerland, DYCONEX coordinates the manufacturing of highly miniaturised and customised printed circuit boards dedicated to the medtech sector. The industrial footprint relies on a production facility equipped with advanced machinery and specialized cleanroom spaces designed for high-precision electronics. Operating continuously since its establishment in 1964, the organization focuses its technical expertise on developing high-reliability, IPC Class III printed circuit boards and advanced interconnect solutions. The product portfolio directly supports critical healthcare applications, supplying electronic components for pacemakers, defibrillators, cochlear implants, hearing aids, and complex medical imaging equipment. To maintain its strict quality standards and technological differentiation, the manufacturer integrates a dedicated research and development department. The operational capacity of the site is sustained by a workforce of approximately 200 highly skilled professionals who oversee the engineering of specialized flexible, rigid-flex, and ultra-thin circuit solutions. By concentrating its capabilities on advanced medical-grade components, the Swiss manufacturer functions as a premier supplier for medical device manufacturers requiring uncompromising precision in their technical supply chain.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Hardware & Electronics
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2024 | BALMORAL FUNDS | XIRGO TECHNOLOGIES | UNITED STATES | Sensors & Optics |
| 08/2024 | BAIN CAPITAL | Somacis | ITALY | Electronic Components |
| 06/2024 | CAPITAL CROISSANCE | STID | FRANCE | IoT & Connected Objects |
| 06/2024 | RESIDEO TECHNOLOGIES | SNAP ONE | UNITED STATES | IoT & Connected Objects |
| 02/2024 | TELEDYNE TECHNOLOGIES INCORPORATED | ADIMEC | NETHERLANDS | Sensors & Optics |
| 12/2023 | AMPHENOL CORPORATION | PCTEL | UNITED STATES | IoT & Connected Objects |
| 12/2023 | ORICA | TERRA INSIGHTS | CANADA | Sensors & Optics |
| 11/2023 | MILLAR | SENTRON | NETHERLANDS | Sensors & Optics |
| 11/2023 | IRD INVEST | IAGONA | FRANCE | IT Equipment |
| 09/2023 | HID GLOBAL | EVOLIS | FRANCE | IoT & Connected Objects |
REFERENCES
Revenue range: 25M - 50M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DYCONEX by Somacis are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: dyconex
Acquirer: somacis